FDA’s Advisory Committee Rebuild Will Reshape Protocol Feedback Before Sponsors Realize It
FDA's September 2026 adcomm recruitment push signals shifts in protocol feedback loops that sponsor clinops and sites can't afford...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Artificial Intelligence in Clinical Trials Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy manufacturing compliance Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
FDA's September 2026 adcomm recruitment push signals shifts in protocol feedback loops that sponsor clinops and sites can't afford...
JAMA's 2026 editorial exposes how "pragmatic trial" has been stretched beyond recognition, threatening regulatory credibility and real-world evidence quality.
AI deployment in clinical studies requires validation framework and governance structure to address compliance gaps and enable safe implementation.
CRScube and Mednet demonstrate integration-free EHR-to-EDC tool designed to reduce manual transcription errors and streamline clinical data capture.
Oculis to present licaminlimab data at AAO 2026 following year-end PREDICT-1 readout in genotype-selected dry eye patients.
Rezdiffra shows consistent efficacy across common MASH genetic risk variants in Phase 3 analysis, addressing prescribing concerns for high-risk...
Enfortumab vedotin-pembrolizumab shows durability advantage over chemotherapy at three-year follow-up in bladder cancer trial EV-302.
Regeneron will present updated C-POST overall survival data for adjuvant cemiplimab in high-risk CSCC at ESMO 2026 on October...
CDER's new Office of Innovation and Clinical Trial Modernization fuses AI and RWE policy under one roof. That structural...
Most sites undercharge on research-paid items because no one reconciles the sponsor budget against the charge master. Here is...